REFERENCES:

1. Ali Hany, York Peter, Ali Ahmed, Blagden Nicholas. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. *J. Controlled Release*. 2011; 149:175–181.
2. Arun Jenish J, Lodha Rakesh and Kabra Sushil K. Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial. *BMC Pediatrics*. 2012; 12:1-7.
3. Borgstrom et al. Lung deposition of budesonide inhaled via Turbuhaler®: a comparison with terbutaline sulphate in normal subjects. *Eur Respir J*. 1994; 7: 69–73.
4. Bose et al. Application of spray granulation for conversion of a nanosuspension into a dry powder form. *Euro. J. Pharm Sci*. 2012:1-9.
5. Carlos Rodrigo, Gustavo Rodrigo. Salbutamol treatment of acute severe asthma in the MDI versus hand-held nebulizer. *American J. Emer. Med*. 1998; 16: 642-637.
6. Chattopadhyay et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. *Advanced Drug Delivery Reviews*. 2007; 59:444–453.
7. Detroja Chetan, Chavhan Sandip, Sawant Krutika. Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study, *J. Sci Pharm*. 2011; 79:635–651.
8. Dolenc A., Kristl J., Baumgartner S., Planinsek O.. Advantages of celecoxib nanosuspension formulation and transformation into tablets. *Int. J. Pharm.* 2009; 376: 204-212.
9. Gao Lei et al. Preparation of a chemically stable quercetin formulation using nanosuspension technology. *Int. J. Pharm.* 2011; 404: 231-237.
10. Ghosh Indrajit, Bose Sonali, Vippagunta Radha, Harmon Ferris. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. *Int. J. Pharm*. 2011; 409:260–268.

11. Gouda et al. Development and validation of selective UV spectrophotometric analytical method for budesonide pure sample. *J. Pharm. Sci*. 2011:158-161.
12. Hou Shuguang, Hindle Michael , Byron Peter R.. A stability-indicating HPLC assay method for budesonide. *J. pharm. & Biomed. Ana*.2011; 24: 371-380.
13. http://en.wikipedia.org/wiki/Budesonide, assessed on date 11/04/2016.
14. http://www.drugbank.ca/drugs/DB01001, assesed on date 11/04/2016.
15. Huang Y. et al. The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability. *AAPS Pharm. Sci.Tech*. 2013; 14: 1236-1243.
16. Kaplan Alan, Ryan Dermot. The role of budesonide/formoterol for maintenance and relief in the management of asthma. *J. pulm. pharmacol. and Therap*. 2010; 23:88–96.
17. Kassem M. A. et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. *Int. J. Pharm.* 2007; 340: 126-133.
18. Kayser et al. Formulation of amphotericin B nanosuspension for oral administration. *Int. J. Pharm.* 2003; 254: 73-75.
19. Kirstein Norma. Development and characterisation of buparvaquone nanosuspensions for pulmonary delivery in the treatment of Pneumocystis pneumonia. University of Berlin. 2006:7-97.
20. Lakshmi Prasanna, Giddam Ashwini kumar. Nanosuspension technology: a review. *Int. J. Pharm. and Pharm. Sci*. 2012; 2:35-40.
21. Larsson Miller, Selroos O. Advances in Asthma and COPD Treatment: Combination Therapy with Inhaled Corticosteroids and Long-Acting beta2-Agonists. *Current Pharm. Design*. 2006; 12: 3261-3279.
22. Liu et al. Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling. *Int. J. Pharm*. 2011; 411: 215–222.
23. McFadden et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. *J Allergy Clin Immunol*. 1999; 104(1):46-52.
24. Mukherji G. and Aggarwal N.. Quantitative estimation of salbutamol sulphate by derivative UV Spectroscopy. *Int. J. Pharm*. 1992; 86:153-158.
25. Nakarani M., Misra A.K., Patel J.K., Vaghani S.S. Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation. *DARU*. 2010; 18: 84-90.

26. Pandya Vikram M., Patel Jayvadan K., and Patel Dhaval J.. Formulation and Optimization of Nanosuspensions for Enhancing Simvastatin Dissolution Using Central Composite Design", *J. Disso. Tech*. 2011:40-45.
27. Patel Dhaval J., Patel Jayvadan K. and Pandya Vikram M.. Improvement in the dissolution of poorly water soluble drug using media milling technique. *Thai J. Pharm*. Sci.2010; 34:155-164.
28. Patravale V. B., Date Abhijit A. and Kulkarni R. M.. Nanosuspensions: a promising drug delivery strategy. *J. Pharm and pharmcol.* 2004; 1(56):827–840.
29. Razzouk et al. A comparison of the bronchodilatory effect of 50 and 100 mg salbutamol via Turbuhaler® and 100 mg salbutamol via pressurized metered dose inhaler in children with stable asthma. *Int. J. Pharm*. 1999; 180:169–175.
30. Shah Siddharth N. API Textbook of Medicine. The association of Physicians. India. 2003; 7: 291-293.
31. Shrikhande S. S., Rao A., Ambekar A., Bajaj A. N. Metered Dose Inhalation Formulations of Salbutamol Sulphate Using Non-CFC Propellant Tetrafluoroethane. *Int. J. of Pharm Sci and Drug Research*. 2011; 3(4): 292-296.
32. Singh et al. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. *Euro. J. Pharm Sci. and Biopharm* 2011; 78:441–446.
33. Steckel Hartwig, Pichert Lars, Muller B.. Influence of process parameters in the ASES process on particle properties. *Euro. J. Pharm Sci. and Biopharm.* 2004; 57: 507-512.
34. Svedmyer Nils, Simonsson B. G.. Drugs in the treatment of asthma. *Pharmec.Ther.*1978; 3:397-440.
35. Swarbrick James. Encyclopedia of pharmaceutical technology. Informa Healthcare. USA. 2007; 1(3):1279-1290.
36. Thakkar H., Patel B., Thakkar S.. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. *J. Pharmacy & Bio Allied Sci.* 2011; 3: 426-434.
37. Toshiyuki Niwa, Satoru Miura, Kazumi Danjo. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical

animal studies – Development of particle design method. *Int. J. Pharm.* 2011; 405: 218–227.

38. Van et al. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze–dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. *Int. J. Pharm*. 2007; 338:198–206.
39. Wei Li et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. *Int. J. Pharm.*2011; 408; 157-162.
40. Xiong Ruolan et al. Preparation and characterization of intravenously injectable nimodipine nanosuspension. *Int. J. Pharm.* 2008; 350:338-343.
41. Yancai Wang et al. Development and invitro evaluation of deacetyl mycoepoxydiene nanosuspension. *J. Colloids and Surfaces B: Biointerfaces.* 2011; 83: 189-197.
42. Yang Wei, Johnston Keith P, Williams Robert . Comparison of bioavailability of amorphous versus crystalline Itraconazole nanoparticles via pulmonary administration in rats. *Europ. J. Pharm. and Biopharm*. 2010; 75:33–41.
43. Yao Liping et al. In vitro and in vivo evaluation of camptothecin nanosuspension: A novel formulation with high antitumour efficacy and low toxicity. *Int. J. Pharm.* 2012; 423: 586-588.